Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cemiplimab + S095029
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination of **cemiplimab**, an anti-PD-1 monoclonal antibody marketed as Libtayo and developed by Regeneron Pharmaceuticals and Sanofi, and **S095029**, an anti-NKG2A monoclonal antibody developed by Servier. The combination is in clinical trials for advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Cemiplimab blocks the PD-1 receptor on T cells to enhance immune response against tumors, while S095029 targets NKG2A, an inhibitory receptor on natural killer (NK) and cytotoxic T cells, aiming to lift suppression of these cell populations and further boost anti-tumor immunity. This combination is being tested for enhanced immunotherapeutic effects compared to single-agent treatment[1][2][3][5][8].
- Other names
- cemiplimab-rwlcanti-PD1 antibody (cemiplimab)anti-NKG2A antibody (S095029)
02
Targets
KLRC1 (Killer cell lectin-like receptor subfamily C member 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cemiplimab + S095029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cemiplimab + S095029.